Saxenda is FDA-approved for chronic weight management and is delivered by injection
Blue Crosss move is among the latest signs the surge in demand for GLP-1s, which doctors say provide broad health benefits to their patients, is pushing insurers and employers toward a financial breaking point
Peak Wellness is medication with transparent pricing attached
The optimal approach for many patients involves combining strategies
On April 1, 2026, the FDA approved Eli Lillys FOUNDAYO (orforglipron) , the second oral GLP-1 approved for obesity, and arguably the one with the more patient-friendly convenience profile
Furthermore, I mean, these haven't been studied, and I talked to people who had ranging from moderate to severe side effects from taking various peptides, ranging from gallstones to just nerve pain, kidney stones. In your article, you talked with someone who got acute necrotizing pancreatitis